Get the Stockscreener App
4.65
80.23%
2.07
After Hours:
4.15
-0.50
-10.75%
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Offerings News Live Feed - StockTitan
Stock market news: Lipella Pharmaceuticals +96.90%, Digital Turbine +66.19% among top gainers as investors assess corporate earnings report - Business Upturn
Stock market news: Lottery.com surged by 93.55% while Lipella Pharmaceuticals posted rise of 86.44% during mid day trading - Business Upturn
Strong Earnings Drive Digital Turbine (APPS) Stock’s Market Rally - Stocks Telegraph
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook - Benzinga
Clinical Trials News Live Feed - StockTitan
Stock market today: Lipella Pharmaceuticals +99.22%, Digital Turbine +68.90% among top gainers in early trading - Business Upturn
Dow Edges Higher; US Weekly Jobless Claims Increase - Benzinga
Stock market today: Lipella Pharmaceuticals jumped by 98.06% whereas ReTo Eco-Solutions plunged by 38.75% in early trading - Business Upturn
FDA Greenlight Sends Lipella Pharma Stock Skyrocketing 160% - Wall Street Pit
Lipella Pharmaceuticals (LIPO) Stock Sees Strong Pre-Market Rally - Stocks Telegraph
FDA approves Lipella's oral treatment access program - Investing.com
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewswire
Revolutionary Oral Disease Treatment Gets FDA Early Access Approval6M Americans Could Benefit - StockTitan
Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment - Mugglehead
Full Stock Market News from 2025-02-01 - StockTitan
Graft Versus Host Disease FDA Approvals, Clinical Trials, Pipeline Insights and Companies | DelveInsight - Barchart
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com - Defense World
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 - MSN
Lipella Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Biden-Harris Administration Awards Record-Breaking $183B in Federal Contracts to Small Businesses, Marking Fourth Consecutive Year of Growth - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement - GlobeNewswire Inc.
Lipella Pharmaceuticals Inc. Announces Second Closing of Offering 2024 - Defense World
SABBY MANAGEMENT, LLC Acquires 60,325 Shares in Lipella Pharmace - GuruFocus.com
Elevai Labs (NASDAQ:ELAB) Announces Resignation of Director - Defense World
Lipella Pharmaceuticals Inc. Enters into Agreement with Spartan Capital Securities, LLC and Closes Initial OfferingThe pharmaceutical company Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) recently disclosed in an 8-K filing with the U.S. Securities and - Defense World
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewswire
Lipella Pharmaceuticals Cancels Special Meeting Due to Lack of Quorum - Defense World
CMC Pharmaceuticals - Contract Pharma
Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times
Lipella Pharmaceuticals Enters into Placement Agent and Consulting Agreements - Defense World
Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com
Lipella Pharmaceuticals reschedules special meeting - Investing.com
Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan
Critical Review: Lipella Pharmaceuticals (LIPO) & Its Peers - Defense World
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):